Oncolytics Biotech Inc Financials

No, Oncolytics Biotech Inc (ONCY) reported a net income of -$28.8M in fiscal year 2025.

Oncolytics Biotech Inc (ONCY) reported diluted earnings per share of $-0.30 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Oncolytics Biotech Inc (ONCY) had EBITDA of -$28.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

Oncolytics Biotech Inc (ONCY) generated -$20.1M in free cash flow during fiscal year 2025. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Oncolytics Biotech Inc (ONCY) generated -$20.1M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

Oncolytics Biotech Inc (ONCY) had $7.6M in total assets as of fiscal year 2025, including both current and long-term assets.

Oncolytics Biotech Inc (ONCY) invested $6K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Oncolytics Biotech Inc (ONCY) invested $13.3M in research and development during fiscal year 2025.

Oncolytics Biotech Inc (ONCY) had 116M shares outstanding as of fiscal year 2025.

Oncolytics Biotech Inc (ONCY) had a current ratio of 1.12 as of fiscal year 2025, which is considered adequate.

Oncolytics Biotech Inc (ONCY) had a debt-to-equity ratio of -3.00 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

Oncolytics Biotech Inc (ONCY) had a return on assets of -379.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Based on fiscal year 2025 data, Oncolytics Biotech Inc (ONCY) had $5.2M in cash against an annual operating cash burn of $20.1M. This gives an estimated cash runway of approximately 3 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Oncolytics Biotech Inc (ONCY) has negative shareholder equity of -$3.8M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

Oncolytics Biotech Inc (ONCY) has an earnings quality ratio of 0.70x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.